Entropy Neurodynamics Secures South African Patent No. 2025/03086 for Psilocin Crystalline Forms to 2043

Aditi Sarkar

09 November 2026 03:33 PM AEDT

Entropy Neurodynamics Secures South African Patent No. 2025/03086 for Psilocin Crystalline Forms to 2043

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Entropy Neurodynamics Limited (ASX:ENP), a clinical-stage biotechnology company developing precision-controlled psychedelic therapies, has been granted a South African patent covering proprietary crystalline forms of psilocin, with protection extending through to September 2043, further expanding the company's international intellectual property portfolio supporting its TRP-8803 development program.

Key Points

South African Patent No. 2025/03086, titled "Psilocin Crystalline Forms," has been granted to Entropy Neurodynamics, covering crystalline forms of psilocin and associated pharmaceutical compositions and methods of preparation.
The patent follows the earlier 2026 grant of a corresponding Australian patent (No. 2023343417) covering the same subject matter.
Patent protection runs for 20 years from 12 September 2023, subject to applicable renewal fees, providing coverage through to 2043.
The company is progressing additional patent applications across key jurisdictions including the US, covering proprietary formulations, treatment methods, biomarker-guided dosing and indication-specific applications including Binge Eating Disorder and Irritable Bowel Syndrome.

South African Patent Details and Scope

The South African patent, numbered 2025/03086 and titled "Psilocin Crystalline Forms," covers crystalline forms of psilocin — described as the active metabolite of psilocybin — along with associated pharmaceutical compositions and methods of preparation. According to the filing, these crystalline forms offer improved stability, solubility and consistency compared with conventional psilocin formulations, addressing considerations in the development and manufacture of pharmaceutical-grade therapeutics. The patent has a term of 20 years from 12 September 2023, subject to applicable renewal fees, providing protection through to 2043.

Relationship to TRP-8803 Program and Existing IP Portfolio

The newly granted patent complements Entropy's existing intellectual property portfolio supporting TRP-8803, the company's proprietary precision-controlled intravenous psilocin treatment platform. The company's broader IP portfolio now includes granted Australian patents covering its proprietary precision-controlled IV dosing methodology and psilocin crystalline forms, together with South African patents protecting fibromyalgia treatment methods and, following this latest grant, crystalline psilocin formulations. The filing states the latest grant broadens the company's IP position across complementary aspects of psilocin-based drug development.

International Patent Applications in Progress

Beyond the patents already granted in Australia and South Africa, Entropy disclosed it is progressing additional patent applications across key international jurisdictions, including the United States. These applications cover proprietary formulations, treatment methods, biomarker-guided dosing and indication-specific applications, including Binge Eating Disorder and Irritable Bowel Syndrome. CEO Jason Carroll stated in the filing that the company is "systematically building a global IP portfolio designed to support the long-term commercial potential of TRP-8803," and that the approach is intended to strengthen the company's position in future licensing and strategic partnership discussions.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.